Viatris Corp (VTRS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

The diversified portfolio of Viatris Inc. (VTRS) supports sales stability, which correlates with the dynamics of the EV/EBITDA multiple. Optimized logistics reduce costs, yet pricing pressure is forcing the company to develop biosimilars. The current value is 8.14, allowing for an assessment of the holding's capital resilience to external shocks and the stock's current market margin of safety.

VTRS Viatris Inc: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization in the range 11/23/2025 - 11/14/2026

Analytical breakdowns for Viatris Inc.

- current price and projected stock value:

Stock Price Viatris Corp|VTRS - Fair Value Consensus

- market capitalization indicators:

Market Value Mylan|VTRS - Total Enterprise Value

- book value of equity indicators:

Net Assets per Single Share Viatris|VTRS - Company Book Value|Market Capitalization to Book Value Ratio viatris.com|VTRS - Total Business Assets

- debt and liquidity data:

- business earnings and investment ratios data:

VTRS - Net Financial Result|Projected Future Earnings Viatris Inc.|VTRS - P/E Multiple|Projected Price to Earnings Viatris Inc.|VTRS - Company Value to Earnings Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Mylan|VTRS - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Viatris|VTRS - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months viatris.com|VTRS - Expected net earnings per share growth this year|Expected earnings per share growth for next year Viatris Inc.

- sales revenue and business income indicators:

VTRS - Company Sales Revenue|Projected Sales Volume Viatris Corp|VTRS - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Mylan

Fundamental company valuation:Viatris Corp VTRS

Viatris Inc. (VTRS) is optimizing internal processes following its business spin-off, making debt load control critically important. The ratio correlates the total enterprise value, including liabilities, to earnings before interest, taxes, depreciation, and amortization. A decrease in this value signals that the asset is undervalued, although extreme lows may indicate systemic degradation of the company. The investor determines the entry point by analyzing the EV/EBITDA multiple trend for a return to historical averages.

Main competitors

EV/EBITDA Multiple LLY (Eli Lilly & Co.)|Business Value to Operating Income Before Depreciation ABBV|AZN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA novartis.com|Merck (MRK) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NVO (Novo Nordisk AS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AMGN (Amgen Corporation) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation PFE (Pfizer Corp)|EV/EBITDA Multiple SNY|Total Company Value to Operating Income Before Depreciation Ratio bms.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GlaxoSmithKline GSK|TAK: Enterprise Value to Operating Income Before Depreciation|Teva Pharmaceutical Industries Ltd. - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Dr. Reddy's Labs (RDY)|ROIV (Roivant Sciences Ltd.) - Enterprise Value to EBITDA Ratio|ZLAB (zailaboratory.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BHC (Bausch Health) - EV/EBITDA Multiple|Cosmos Health, Inc. (COSM) - Total Company Value to Operating Income Before Depreciation Ratio